Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Moreover, the platform is useful in other disease states. I can’t think of a single infectious disease pathogen (viral, bacterial, prion, etc…) that survive a legion of targeted dendritic cells. The infectious disease market is massive. Combining the solid tumor market with ID, I’d give NWBO a conservative valuation of $150 billion to $200 billion. Those who know what they hold solidly understand this.
Thank you Stonk!
Morning. As I understand it, there is no delay. The MHRA can have a “clock off” period up to sixty days. In most cases they take a portion or all of the sixty days. The point of the “clock off” is to get up to speed on things the reviewers may not be familiar with, not to handle RFIs, ect… (as I understand it). The MHRA does not inform if they are taking a “clock off” period. So what ever day you think NWBO files were submitted/accepted, add up to sixty days. This has been my experience, if someone has a different understanding please share.
Bio
They don’t have the b@llz to go on any of those aforementioned platforms. They would be destroyed after their first irrelevant post.
Computershare. Stock can not be loaned or touched by anyone but the owner. It’s a lock box and protects the company.
I can say that Linda has a strict policy of not sending a Press Release until the hard copy of acceptance is sitting on her desk, she does not PR on electronic responses. All lawyers would agree with this policy. A hard copy response can take a week or two to arrive by snail mail. So there will be no word for a week or two after they have submitted, which could have already happened.
Wells, Wells, Wells…that sWells Hspooner!
How Wells everybody doing today?!!
Wait? Ex can read? Who knew?!
Additionally, They saw those results in patients with DNAH gene mutation, and quick review shows that patients responded favorable to chemotherapy with that mutation.
Homogenous study populations are notoriously unreliable. This Chinese study is a problem clinically based on that alone.
Spot on biosect!
Nice Mav!
Nov 20th will be a “BIG” day for all of of us longs! I suggest everyone tune in. “You can’t stop a speeding freight train by standing in front of it with a wheelbarrow full of bullshit, but be my guest and try. We will scrape you off the tracks!
https://www.eventscribe.net/2022/SNO/agenda.asp
Minutes 28 thru 30
Just an observation.
The new Covid booster designed to be protective against omicron variant got FDA approval with data from mice -no human subjects!
Mercks HPV vaccine got approval with similar loose science.
However, DCVax which has more than science backing it is treated as a PhD dissertation with heightened scrutiny.
Losing faith in the system on a daily basis.
What they say seems correct. You have to be your own advocate. Those who rely on the system will be left without a seat when the music stops.
“In 2018 LL made a public statement after the Translational Medicine article came out saying “may improve survival.”
This is the first time she has affirmed the positive results in public by saying “improves survival…”. This confirmation and admission from the principal investigator is what we have been waiting for all along.
Clearly the journal is done an has been accepted. No way would she say this unless the data received peer approval.
Her reputation is too valuable to risk if there was any possibility that someone can refute this claim.”
*quoting a conversation I had with a head & neck surgeon
Wonderful breakdown! Thanks H!
Typically 80% of pharma revenues comes from the US market and 20% from the rest of the world. Reason being pharma increases the price of the sale of their drugs in the US to compensate for the lower prices paid by other countries. As I understand it there won’t be a pharma pricing scheme for DCVax, it will be one reasonable price for all countries. Aside from over all cost savings on treatment, it means that revenue stream shifts to a much more equal footing between the US market and the world. Perhaps even the higher revenue stream coming from the rest of the world. My point is that approvals gained outside the US means more in terms of revenue than they would with a typical pharma drug. The approvals coming from the UK, Canada, EU are financial windfalls.
Congrats Scotty!
Great research flipper! Thank you!
Certainly matches the RTOR timeline I believe we are in.
“Assuming we were at week 10 when Dr. Ashkan spoke on 6/23 and that a pre-NDA/BLA meeting happened that week as all the players were present, we would now be at week 12 RTOR process. Potentially NWBO could announce submission at week 16, about 8/4. Then approval anytime after 9/1.”
…and very soon.
Assuming we were at week 10 when Dr. Ashkan spoke on 6/23 and that a pre-NDA/BLA meeting happened that week as all the players were present, we would now be at week 12 RTOR process. Potentially NWBO could announce submission at week 16, about 8/4. Then approval anytime after 9/1.
https://twitter.com/richardeno16/status/1545251745554526209?s=21&t=CfI9CGjfFERE4oG4Nw8f8g
Remember Pazdur et al published in Annals of Oncology in January of 2022 and then updated and republished again as Editors choice in March? That article directly impacts our paper, meaning you would pull the paper from publication review and rewrite to include Pazdur’s comments. No researcher worth their salt would pass up citing an article by Pazdur that supports their clinical trial. So now you know why the paper was submitted when it was and there is nothing disgraceful about that.
I find nothing unusual that would indicate “problems” with the publication. My experience with journals is the more “reputable” journals take longer. Example, NEJM can take up to six months to publish. Which would mean if NEJM were the journal and we submitted to in May, we are looking at the latest publication date by October. Standard fair. That said, I believe it’s coming much sooner than that.
Ha! Good one biosect!
Here is the you tube link to Linda’s presentation:
What’s going on with the combo trial? Here is a question from Doc T to Danish on Twitter:
“Can you post a link to the video you’re referencing where LL says 1/2 of combo patients are living 100 months? Thanks so much.”
Our man Danish’s smashing reply:
$NWBO
— 🇩🇰 The Danish Dude 🇩🇰 (@FlemmingBruce) August 7, 2022
Yes I can.https://t.co/hy19ij98bs
And the combo trialhttps://t.co/gkARMFpjCD https://t.co/hRpesUJRP9 pic.twitter.com/nMowypMasQ
Reminder that there is an ongoing investigation into market manipulation. After hedge funds go bankrupt due to naked shorting and the like, individuals connected to those organizations will face criminal charges and jail time for what they did to try and stop the most effective treatment for solid tumors ever discovered. #NWBO
US investigates potential short selling abuses
https://www.ft.com/content/08899017-2994-4990-84e8-4a6efb7c57c6
Thanks Doc! I appreciate your insight and completely agree.
The patentees include cognate and nwbo.
Marriage with CRL coming?
Thanks for sharing!
NWBO short squeeze coming, please take heed.
The market has been of s source of great pain to a lot of people (fathers, mothers, sisters, brothers, friends, etc…) Please take care of your mental health and get help if you or a loved one is not doing well. Regardless of what your position is on this board, people love you and no matter what happens you deserve to be in this world. Don’t do something impulsive and foolish, leaving those who care about you the pain of loss. Be the example to others on how to be strong and get help. Things can go bad quickly in this game, but the beauty in that is you can always rebuild and there are plenty of people here who would give you advice and help you do that. Stay with us.
They were let off east ae, but I still have never seen them make a retraction on a clinical trial.
The fact AACR took down the old article and put up a new one is breathtaking! I haven’t seen that happen before. Here’s the link followed by the quote:
https://aacrjournals.org/cdnews/pages/noted-this-week
“The prior statement regarding DCVax-L, published May 13, has been removed. An updated version of the statement appears below.]
Since the first announcement of the DCVax-L Phase 3 glioblastoma (GBM) trial results presented by Dr. Paul Mulholland on May 10, 2022, at the New York Academy of Sciences (NYAS) Conference on Frontiers in Cancer Immunotherapy, Northwest Biotherapeutics ("Company") has indicated that our prior statement did not include certain information contained in the presentation, including the updated primary and secondary endpoints of the trial.
The Company believes the presentation shows that DCVax-L-treated patients, when compared to external controls, exhibited a clinically meaningful and statistically significant extension of survival in both newly diagnosed and recurrent GBM, which are the two updated endpoints of the trial. For details regarding the full presentation at NYAS, please see the following:
https://virtualtrials.org/dcvax/dcvax.pdf
Given that the journal article is not out yet and Annals of Oncology has yet to publish the August edition, I was thinking what would be the most appropriate title for the article. The title needs to communicate everything that Linda Liau et al needs to be say in the shortest possible title. I could only come up with this:
“Eff You Night King! We won!”
Maybe use two exclamation points for emphasis? Thoughts?
Thank you for the added knowledge and I completely agree with you. I’m hoping for that route as well.
Cheers!
Roche acquired Genentech in a similar manner. Roche bought in initially, then waited 10 years to let the stock grow before buying GNE. This tells me that they have a preferred partner and they are hammering out details.